Cargando…

Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic

Objective: In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19) that resulted in a global pandemic with substantial morbidity and mortality. Currently, there is no specific treatment or app...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuen, Kevin C.J., Blevins, Lewis S., Findling, James W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833469/
https://www.ncbi.nlm.nih.gov/pubmed/33471683
http://dx.doi.org/10.4158/EP-2020-0308
_version_ 1783642073169133568
author Yuen, Kevin C.J.
Blevins, Lewis S.
Findling, James W.
author_facet Yuen, Kevin C.J.
Blevins, Lewis S.
Findling, James W.
author_sort Yuen, Kevin C.J.
collection PubMed
description Objective: In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19) that resulted in a global pandemic with substantial morbidity and mortality. Currently, there is no specific treatment or approved vaccine against COVID-19. The underlying associated comorbidity and diminished immune function of some pituitary patients (whether caused by the disease and its sequelae or treatment with excess glucocorticoids) increases their risk of contracting and developing complications from COVID-19 infection. Methods: A review of studies in PubMed and Google Scholar published between January 2020 to the time of writing (May 1, 2020) was conducted using the search terms ‘pituitary,’ ‘coronavirus,’ ‘COVID-19’, ‘2019-nCoV’, ‘diabetes mellitus’, ‘obesity’, ‘adrenal,’ and ‘endocrine.’ Results: Older age and pre-existing obesity, hypertension, cardiovascular disease, and diabetes mellitus increase the risk of hospitalization and death in COVID-19 patients. Men tend to be more severely affected than women; fortunately, most men, particularly of younger age, survive the infection. In addition to general comorbidities that may apply to many pituitary patients, they are also susceptible due to the following pituitary disorder–specific features: hypercortisolemia and adrenal suppression with Cushing disease, adrenal insufficiency and diabetes insipidus with hypopituitarism, and sleep-apnea syndrome and chest wall deformity with acromegaly. Conclusion: This review aims to focus on the impact of COVID-19 in patients with pituitary disorders. As most countries are implementing mobility restrictions, we also discuss how this pandemic has affected patient attitudes and impacted our decision-making on management recommendations for these patients. Abbreviations: ACE = angiotensin-converting enzyme; AI = adrenal insufficiency; ARB = angiotensin receptor blocker; ARDS = acute respiratory disease syndrome; COVID-19 = coronavirus disease 2019; CPAP = continuous positive airway pressure; DI = diabetes insipidus; DM = diabetes mellitus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
format Online
Article
Text
id pubmed-7833469
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-78334692021-01-26 Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic Yuen, Kevin C.J. Blevins, Lewis S. Findling, James W. Endocr Pract Review Articles Objective: In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19) that resulted in a global pandemic with substantial morbidity and mortality. Currently, there is no specific treatment or approved vaccine against COVID-19. The underlying associated comorbidity and diminished immune function of some pituitary patients (whether caused by the disease and its sequelae or treatment with excess glucocorticoids) increases their risk of contracting and developing complications from COVID-19 infection. Methods: A review of studies in PubMed and Google Scholar published between January 2020 to the time of writing (May 1, 2020) was conducted using the search terms ‘pituitary,’ ‘coronavirus,’ ‘COVID-19’, ‘2019-nCoV’, ‘diabetes mellitus’, ‘obesity’, ‘adrenal,’ and ‘endocrine.’ Results: Older age and pre-existing obesity, hypertension, cardiovascular disease, and diabetes mellitus increase the risk of hospitalization and death in COVID-19 patients. Men tend to be more severely affected than women; fortunately, most men, particularly of younger age, survive the infection. In addition to general comorbidities that may apply to many pituitary patients, they are also susceptible due to the following pituitary disorder–specific features: hypercortisolemia and adrenal suppression with Cushing disease, adrenal insufficiency and diabetes insipidus with hypopituitarism, and sleep-apnea syndrome and chest wall deformity with acromegaly. Conclusion: This review aims to focus on the impact of COVID-19 in patients with pituitary disorders. As most countries are implementing mobility restrictions, we also discuss how this pandemic has affected patient attitudes and impacted our decision-making on management recommendations for these patients. Abbreviations: ACE = angiotensin-converting enzyme; AI = adrenal insufficiency; ARB = angiotensin receptor blocker; ARDS = acute respiratory disease syndrome; COVID-19 = coronavirus disease 2019; CPAP = continuous positive airway pressure; DI = diabetes insipidus; DM = diabetes mellitus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2 Elsevier Inc. 2020-08 2020-12-28 /pmc/articles/PMC7833469/ /pubmed/33471683 http://dx.doi.org/10.4158/EP-2020-0308 Text en Copyright © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Articles
Yuen, Kevin C.J.
Blevins, Lewis S.
Findling, James W.
Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic
title Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic
title_full Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic
title_fullStr Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic
title_full_unstemmed Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic
title_short Important Management Considerations In Patients With Pituitary Disorders During The Time Of The Covid-19 Pandemic
title_sort important management considerations in patients with pituitary disorders during the time of the covid-19 pandemic
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833469/
https://www.ncbi.nlm.nih.gov/pubmed/33471683
http://dx.doi.org/10.4158/EP-2020-0308
work_keys_str_mv AT yuenkevincj importantmanagementconsiderationsinpatientswithpituitarydisordersduringthetimeofthecovid19pandemic
AT blevinslewiss importantmanagementconsiderationsinpatientswithpituitarydisordersduringthetimeofthecovid19pandemic
AT findlingjamesw importantmanagementconsiderationsinpatientswithpituitarydisordersduringthetimeofthecovid19pandemic